Marie Curie, née Maria Sklodowska, was born in Warsaw on November 7, 1867. She died July 4th 1934.
I could read about this Polish-born French scientist, famous for her work on radioactivity and twice a winner of the Nobel Prize. for. hours! I have referenced her in several of my blog posts already. With Henri Becquerel and her husband, Pierre Curie, she was awarded the 1903 Nobel Prize for Physics. She was later the sole winner of the 1911 Nobel Prize for Chemistry.
She was the first woman to win a Nobel Prize, and she is the first person and only woman to win the award in two different…
A busy month ahead for the Virtual Innovation Centre with two workshops discussing important topics for those Life Science companies becoming more active deal makers:
Growing with Underlying Principles of Drug Development in Mind on 18 November 11.30–12.30 is for early stage companies who need to show their understanding of the underlying principles of drug
development to their stakeholders and ensure they know how to evolve them as the company grows.
In collaboration with
Anatomy of a Research Collaboration Agreement to provide a review of the…
LONDON and CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Blackstone Life Sciences today announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone (NYSE: BX) will provide up to $250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as…
Cambridge, UK, 8th November 2021: Chesterford Research Park is delighted to announce the expansion of existing occupier, CellCentric, within the Mansion House at the heart of the Park. The clinical stage biotechnology company focused on the development of a novel drug for specific cancers has renewed its current lease for Suite 3 in the 19th Century converted manor house, whilst at the same time expanding into Suite 4 within the same building.
Having secured $33m in funding from Morningside Venture Investments at the end of 2020, clinical trials for CellCentric’s novel drug CCS1477 have been…
CAMBRIDGE, UK, 5 November 2021 - today bit.bio announces the first close of their Series B financing of $103 million. New and existing institutional and strategic investors in the Series B round, thus far, include Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent.
The funding will accelerate the clinical development of the company’s proprietary cell coding technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently…
Marks & Clerk, one of the world’s leading intellectual property (IP) law firms, has announced the promotion of Andrea Williams to Partner and the appointment of Senior Associate David Kemp to the Cambridge team, transferring from the London office. Both attorneys are part of the firm’s market-leading UK teams, with Andrea specialising in patents in the biotechnology field and David advising on all aspects of UK, EUTM and international trade mark law and practice. “I am delighted to announce the promotion of Andrea Williams to Partner, and welcome David Kemp to Cambridge. The attorneys in…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH
A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
Cambridge, UK, 1 November 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.
Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to…
Closed Loop Medicine has closed £13 million GBP (c. $17million USD) of new investment from a range of top UK and European venture capital investors. The money has been raised to finance its personalised drug + digital therapy (DTx) combination products which are being developed to improve outcomes for patients and clinicians through precision dosing.
Round led by Ananda Impact Ventures and BGF, joined by a strong syndicate of investors including LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels.The financing was oversubscribedInvestment will fund further platform…
This is the second time writing about the Neurim v Mylan battle “take two” concerning a divisional patent (EP 3 103 443) granted on 30 June 2021 (but expires 12 August 2022). The first article (Neurim v Mylan: Take Two) covered Neurim’s successful application for an expedited preliminary issue trial. That article also covers (some of) the twists and turns of the original Neurim v Mylan battle on the parent patent.
October brought Mylan’s opportunity to convince the Patents Court (Ian Karet sitting as a Deputy High Court Judge) to stay the UK proceedings pending final determination of the…